KR102645911B1 - N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 - Google Patents

N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 Download PDF

Info

Publication number
KR102645911B1
KR102645911B1 KR1020207002894A KR20207002894A KR102645911B1 KR 102645911 B1 KR102645911 B1 KR 102645911B1 KR 1020207002894 A KR1020207002894 A KR 1020207002894A KR 20207002894 A KR20207002894 A KR 20207002894A KR 102645911 B1 KR102645911 B1 KR 102645911B1
Authority
KR
South Korea
Prior art keywords
crystalline form
cyclopropyl
trifluoromethyl
phenyl
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207002894A
Other languages
English (en)
Korean (ko)
Other versions
KR20200018698A (ko
Inventor
비비아 아이드망
라우머 마르쿠스 폰
Original Assignee
이도르시아 파마슈티컬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이도르시아 파마슈티컬스 리미티드 filed Critical 이도르시아 파마슈티컬스 리미티드
Publication of KR20200018698A publication Critical patent/KR20200018698A/ko
Application granted granted Critical
Publication of KR102645911B1 publication Critical patent/KR102645911B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207002894A 2017-07-05 2018-07-04 N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 Active KR102645911B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017066806 2017-07-05
EPPCT/EP2017/066806 2017-07-05
PCT/EP2018/068087 WO2019008034A1 (en) 2017-07-05 2018-07-04 CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE

Publications (2)

Publication Number Publication Date
KR20200018698A KR20200018698A (ko) 2020-02-19
KR102645911B1 true KR102645911B1 (ko) 2024-03-08

Family

ID=63079885

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207002894A Active KR102645911B1 (ko) 2017-07-05 2018-07-04 N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태

Country Status (17)

Country Link
US (2) US11059803B2 (https=)
EP (1) EP3649117B1 (https=)
JP (2) JP2020525475A (https=)
KR (1) KR102645911B1 (https=)
CN (1) CN110831932A (https=)
AU (1) AU2018296423B2 (https=)
BR (1) BR112020000099A2 (https=)
CA (1) CA3067489A1 (https=)
CL (1) CL2020000002A1 (https=)
EA (1) EA202090193A1 (https=)
IL (1) IL271764B2 (https=)
MA (1) MA50972A (https=)
MY (1) MY206357A (https=)
PH (1) PH12020500040A1 (https=)
SG (1) SG11201912881SA (https=)
UA (1) UA126582C2 (https=)
WO (1) WO2019008034A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
EP3649117B1 (en) * 2017-07-05 2024-10-09 Idorsia Pharmaceuticals Ltd Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
TW202128158A (zh) 2019-12-20 2021-08-01 瑞士商愛杜西亞製藥有限公司 包含n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-環丙基)-苯基]-乙醯胺之醫藥組合物
EP4389892A4 (en) * 2021-08-17 2025-12-10 Korea Advanced Inst Sci & Tech Antisense oligonucleotide targeting the CAV3.1 gene and its uses
WO2023240205A1 (en) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Deuterated compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6195684B2 (ja) * 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用
WO2016041892A1 (en) 2014-09-15 2016-03-24 Actelion Pharmaceuticals Ltd Triazole compounds as t-type calcium channel blockers
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
EP3649117B1 (en) * 2017-07-05 2024-10-09 Idorsia Pharmaceuticals Ltd Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide

Also Published As

Publication number Publication date
US20210300894A1 (en) 2021-09-30
KR20200018698A (ko) 2020-02-19
EA202090193A1 (ru) 2020-06-03
MA50972A (fr) 2020-10-14
CL2020000002A1 (es) 2020-07-31
IL271764A (en) 2020-02-27
EP3649117B1 (en) 2024-10-09
US11555025B2 (en) 2023-01-17
IL271764B1 (en) 2023-06-01
SG11201912881SA (en) 2020-01-30
JP2020525475A (ja) 2020-08-27
US11059803B2 (en) 2021-07-13
AU2018296423A1 (en) 2020-02-20
JP2023123679A (ja) 2023-09-05
BR112020000099A2 (pt) 2020-07-07
MY206357A (en) 2024-12-12
CA3067489A1 (en) 2019-01-10
US20200165221A1 (en) 2020-05-28
CN110831932A (zh) 2020-02-21
IL271764B2 (en) 2023-10-01
WO2019008034A1 (en) 2019-01-10
UA126582C2 (uk) 2022-11-02
EP3649117A1 (en) 2020-05-13
AU2018296423B2 (en) 2022-07-28
PH12020500040A1 (en) 2020-10-12

Similar Documents

Publication Publication Date Title
KR102645911B1 (ko) N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태
TWI649314B (zh) 吲唑之合成
EP3433233B1 (en) Novel crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine salt
AU2017256659B2 (en) Synthesis of indazoles
KR20180099787A (ko) Btk 키나아제 억제제의 결정질 형태 및 이의 제조 방법
EP2905282A1 (en) Substituted thiazole or oxazole as P2X7 receptor antagonists
US20220275011A1 (en) Crystalline forms
KR20180005252A (ko) 화합물 (s)-3-｛4-[5-(2-시클로펜틸-6-메톡시-피리딘-4-일)-[1,2,4]옥사디아졸-3-일]-2-에틸-6-메틸-페녹시｝-프로판-1,2-디올의 결정형
US11103512B2 (en) Crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
TWI711612B (zh) 氮雜雙環基取代的三唑類衍生物的可藥用鹽、晶型及製備方法
NZ746469B2 (en) Synthesis of indazoles
HK40009744B (en) Crystalline forms

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210625

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230620

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231220

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240306

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240306

End annual number: 3

Start annual number: 1

PG1601 Publication of registration